semaglutide alzheimer's May Lower Risk for Diabetics evoke study semaglutide in early-stage

Lexaria has repeatedly evidenced higher brain levels upon gross necropsy in rodent studies with other DehydraTECH-processed active ingredients in the past that demonstrated superior safety and efficacy over controls, said John Docherty, Lexaria President and CSO

Seven additional phase 3 readouts are expected throughout this year, covering a range of conditions including type 2 diabetes, obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, and metabolic dysfunction-associated steatotic liver disease

Implementing a structured nutrition strategy is the most reliable way to resolve GLP-1 fatigue

Center for Disease Control and Prevention

PMID: 35608860

It is about how your body processes energy and regulates hormones